Last reviewed · How we verify
NCT04972708: BIPCOVID
Genetics of COVID-19 Risks & Resilience in Bipolar Disorder
trial testing Cross-sectional genetics study in Bipolar Disorder in 400 participants. Status unknown.
1 September 2024
Quick facts
| Lead sponsor | Medical University of Graz |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 July 2021 |
| Primary completion | 1 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Cross-sectional genetics study
Conditions studied
- Bipolar Disorder — all drugs for Bipolar Disorder →
- Covid19 — all drugs for Covid19 →
- Stress — all drugs for Stress →
Sponsor
Medical University of Graz
Who can join
Adults 18 to 75, any sex, with Bipolar Disorder or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BIPGEN is a cross-sectional study on the genetics of bipolar disorder. As a subproject of BIPGEN, BIP-COVID is a cross-sectional genetics study about risks \& resilience in the COVID-19 (Coronavirus disease) pandemic in bipolar disorder (BD) and healthy controls at the Medical University of Graz. Study participants with BD and controls from the well-established BIPLONG and BIPGEN studies will undergo a special BIP-COVID visit, which will include a COVID-19 specific online Lime survey about the psychological burden in the COVID-19 crisis, a COVID-19 antibody test (IgM and IgG), inflammation markers and isolation of DNA from fasting blood. Genotyping of DNA will be done with the GSA V.3 array. Genetic analyses (Polygenic Risk Scores of I. Stress or Major Depression and II. COVID-19 infection established with the programs PLINK, PRSice and R) will be used to analyze the genetic mechanisms of COVID-19 pandemic associated psychological symptoms and COVID-19 infection risk. Systems biology methods will be used to depict protective pathways against COVID-19 infection (e.g. Lithium pathways) and against COVID-19 associated psychiatric symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tryptophan Metabolism in Bipolar Disorder in a Longitudinal Setting.
Fellendorf FT, Gostner JM, Lenger M, Platzer M, et al · · 2021 · cited 20× · PMID 34829665 · DOI 10.3390/antiox10111795
Verify or expand the search:
- PubMed search for NCT04972708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bipolar Disorder
Currently open trials in the same condition.
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
- NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting
Other Medical University of Graz trials
Trials by the same sponsor.
- NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
- NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
- NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04972708 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
- Last refreshed: 10 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing